New global criteria for pediatric CNO aim to boost research & improve care for this rare autoinflammatory bone disease.
What Rheumatologists Should Know About B Cell Tolerance & Autoimmunity
A recent Arthritis & Rheumatology review article explores the immune system’s mechanism for creating B cells that respond to diverse pathogens while preserving immune tolerance & highlights key insights for rheumatologists.
Insights from an Orthopedic Spine Surgeon
Dr. Jay Reidler, an adult & pediatric orthopedic spine surgeon, shares insights from his field & discusses his collaborations with rheumatologists.
Study: Are TNF Inhibitors Safe for Patients with RA-ILD?
Despite anecdotal reports to the contrary, a large observational study concludes that TNF inhibitors, compared with non-TNF biological or targeted synthetic DMARDs, do not cause higher rates of death or respiratory hospitalization in patients with RA-ILD.
New Guidance on Mental Health Screening in Pediatric Rheumatology
Pediatric rheumatologic diseases are characterized by high rates of anxiety & depression known to impact health-related outcomes. CARRA and the ACR developed guidance statements to assess & manage mental health concerns for youths in pediatric rheumatology practice.
New Patient- & Provider-Focused Resources Focus on Improving Lupus Care
With resources and programs running online and on the ground in 47 states, COIN’s projects are having a massive impact on the field of rheumatology.
Benefits of Early Initiation of Biologic DMARDs in pJIA
The early initiation of biologic disease-modifying anti-rheumatic drugs (DMARDs) may reduce the overall disease burden in patients with polyarticular juvenile idiopathic arthritis (pJIA), according to findings from Ringold et al.
Oral Treatment for PsA Inches Closer to FDA Approval
The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
A New Treatment for Fibromyalgia?
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 348
- Next Page »